WO 2004/100659 PCT/US2003/025840

CLAIMS

15

25

30

That which is claimed is:

- 5 1. An isolated toxin from Karlodinium micrum.
 - 2. The isolated toxin according to claim 1 comprising a member selected from the group consisting of KmTx 1, KmTx 2, KmTx 3, KmTx 4, KmTx 5 and KmTx 6.
- 10 3. The isolated toxin according to claim 1 comprising KmTx 1, wherein the KmTx 1 toxin is eluted at about 22-24 minutes of reversed phase HPLC elution of *Karlodinium micrum*.
 - 4. The isolated toxin according to claim 1 comprising KmTx 3, wherein the KmTx 3 toxin is eluted at about 16-18 minutes of reversed phase HPLC elution of Karlodinium micrum.
 - 5. The isolated toxin according to claim 1 comprising KmTx 1, wherein the KmTx 1 toxin is eluted at about 22 to 24 minutes of reversed phase HPLC fractions of a concentrated 80% MeOH tC₁₈ elution of *Karlodinium micrum*.
- 20 6. The isolated toxin according to claim 1 comprising KmTx 3, wherein the KmTx 3 toxin is eluted at about 16-18 minutes of reversed phase HPLC fractions of a concentrated 80% MeOH tC₁₈ elution of Karlodinium micrum.
 - 7. The isolated toxin according to claim 1 comprising a molecular mass of 1362 daltons.
 - 8. The isolated toxin according to claim 1 comprising a molecular mass of 1344 daltons.
 - 9. A method of producing a karlotoxin comprising the steps of: a) culturing *Karlodinium* micrum in a medium suitable for production of toxin; and b) isolating the toxin.
 - 10. The method according to claim 7 comprising a member selected from the group consisting of KmTx 1, KmTx 2, KmTx 3, KmTx 4, KmTx 5 and KmTx 6.
- 11. The method according to claim 7, wherein the toxin is isolated by separation on a HPLC column.

WO 2004/100659 PCT/US2003/025840

- 12. An antibody which binds a Karlodinium micrum toxin.
- 13. The antibody of claim 12, wherein the *Karlodinium micrum* toxin comprises a member selected from the group consisting of KmTx 1, KmTx 2, KmTx 3, KmTx 4, KmTx 5 and KmTx 6.
 - 14. The antibody of claim 13, wherein the antibody is monoclonal.
 - 15. The antibody of claim 13, wherein the antibody is polyclonal.

10

- 16. The antibody of claim 13, wherein the *Karlodinium micrum* toxin comprises KmTx 1 and is eluted at about 22-24 minutes of reversed phase HPLC elution of *Karlodinium micrum*.
- 17. The antibody of claim 13, wherein the *Karlodinium micrum* toxin comprises KmTx 3 and is eluted at about 17 18 minutes of reversed phase HPLC elution of *Karlodinium micrum*.
 - 18. The antibody of claim 13, wherein the *Karlodinium micrum* toxin comprises a molecular mass of 1362 daltons.
- 20 19. The antibody of claim 13, wherein the *Karlodinium micrum* toxin comprises a molecular mass of 1344 daltons.
 - 20. A method of inhibiting a *Karlodinium micrum* toxin comprising contacting an antibody which specifically binds said toxin.

25

- 21. The method of claim 20, wherein the toxin is the toxin comprises a member selected from the group consisting of KmTx 1, KmTx 2, KmTx 3, KmTx 4, KmTx 5 and KmTx 6.
- The method of claim 20, wherein the toxin is the toxin comprises KmTx 1 and is eluted at about 22-24 minutes of reversed phase HPLC elution of *Karlodinium micrum*.
 - 23. The method of claim 20, wherein the toxin is the toxin comprises KmTx 3 and is eluted at about 17-18 minutes of reversed phase HPLC elution of Karlodinium micrum.
- 35 24. An immunoconjugate comprising a Karlodinium micrum toxin linked to an antibody.

WO 2004/100659 PCT/US2003/025840

25. The immunoconjugate of claim 24, wherein the toxin comprises a member selected from the group consisting of KmTx 1, KmTx 2, KmTx 3, KmTx 4, KmTx 5 and KmTx 6.

26. The immunoconjugate of claim 25, wherein the antibody is an anti-tumor antibody.

5

- 27. A composition comprising the immunoconjugate of claim 25.
- 28. A composition comprising the immunoconjugate of claim 26.
- 10 29. A composition comprising a Karlodinium micrum toxin.
 - 30. A composition according to claim 29, wherein the toxin comprises a member selected from the group consisting of KmTx 1, KmTx 2, KmTx 3, KmTx 4, KmTx 5 and KmTx 6.
- 15 31. A composition according to claim 29, wherein the toxin comprises KmTx 1 and is eluted at about 22-24 minutes of reversed phase HPLC elution of *Karlodinium micrum*.
 - 32. A composition according to claim 29, wherein the toxin comprises KmTx 3 and is eluted at about 17-18 minutes of reversed phase HPLC elution of *Karlodinium micrum*.

20

25

34. A method of treating blooms in an aqueous medium caused by *K. micrum* to reduce mortality rate of fish exposed to the treatment, the method comprising:

introducing an algicidal composition in an effective amount to reduce the level of K micrum in the aqueous medium, wherein the algicidal composition comprises potassium permanganate and does not include copper sulfate.

- 35. A method of screening a candidate substance for ability to bind and/or modulate the activity of *K. micrum* toxin, the method comprising:
- contacting the candidate substance with the K. micrum toxin to determine the ability of the candidate substance to interact with the K. micrum toxin.
 - 36. The method according to claim 35, wherein the *K. micrum* toxin comprises a member selected from the group consisting of KmTx 1, KmTx 2, KmTx 3, KmTx 4, KmTx 5 and KmTx 6.

35